ART-PRO: 48-Week Results of DTG + 3TC for Maintenance of Virologic Suppression in Patients With Historical 3TC Resistance

IDWeek 2019; October 2-6, 2019; Washington, DC
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 5-6, 2019; Basel, Switzerland
17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland
This proof-of-concept study demonstrated that switching to DTG + 3TC maintained virologic control in INSTI-naive patients with historical 3TC resistance but no 3TC resistance-associated mutations in proviral DNA at baseline according to Sanger sequencing.
Format: Microsoft PowerPoint (.ppt)
File Size: 157 KB
Released: November 16, 2019

Acknowledgements

Provided by USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
ViiV Healthcare

Related Content

Expert summaries of ART treatment initiation in treatment-naive PWH, including rapid and same-day ART starts, from Clinical Care Options (CCO)

Babafemi Taiwo, MBBS
Program Director
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Released: August 4, 2022

Opciones de cuidado clínico (CCO) presenta a la Dra. Alicia Piñeirúa que explica los principales factores que hay que tener en cuenta a la hora de optimizar el tratamiento antirretroviral en el marco de la supresión viral en pacientes que viven con el VIH y la osteopenia

person default Alicia Piñeirúa Menéndez, MD, MPH Released: August 2, 2022

SIMPL’HIV: switch from standard ART to DTG + FTC in virologically suppressed PWH through Wk 144, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 2, 2022

Dr Darcy Wooten and Clinical Care Options (CCO): Data are emerging on strategies to manage ART-associated weight gain and metabolic complications

Darcy Wooten, MD Released: August 1, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings